Cargando…
Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy
Anticoagulation and antiplatelet therapy are individually mainstays of treatment for multiple cardiovascular conditions. Antiplatelet therapy, most commonly with dual agents, is vital in the setting of coronary artery disease with acute coronary syndrome requiring percutaneous coronary intervention...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161787/ https://www.ncbi.nlm.nih.gov/pubmed/37153377 http://dx.doi.org/10.5114/amsad/161172 |
_version_ | 1785037564671950848 |
---|---|
author | Patail, Haris Sharma, Tanya Bali, Atul D. Isath, Ameesh Aronow, Wilbert S. Haidry, Syed Abbas |
author_facet | Patail, Haris Sharma, Tanya Bali, Atul D. Isath, Ameesh Aronow, Wilbert S. Haidry, Syed Abbas |
author_sort | Patail, Haris |
collection | PubMed |
description | Anticoagulation and antiplatelet therapy are individually mainstays of treatment for multiple cardiovascular conditions. Antiplatelet therapy, most commonly with dual agents, is vital in the setting of coronary artery disease with acute coronary syndrome requiring percutaneous coronary intervention to prevent in-stent complications. A multitude of cardiovascular conditions with increased thromboembolic risk also require anticoagulation, including atrial fibrillation, venous or arterial thrombosis, and prosthetic heart valves to name a few. There is often an overlap in comorbidities as our patient population ages and becomes more complex, frequently necessitating a combination of both anticoagulation and antiplatelet agents, known as “triple therapy”. To reduce or treat thromboembolic disease states as well as reduce platelet aggregation for coronary stent protection, many patients are placed at an increased bleeding risk without compelling evidence of reduction in major adverse cardiac events. With this comprehensive review of the existing literature, we aim to analyse different strategies and durations of triple therapy medication regimens. |
format | Online Article Text |
id | pubmed-10161787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-101617872023-05-06 Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy Patail, Haris Sharma, Tanya Bali, Atul D. Isath, Ameesh Aronow, Wilbert S. Haidry, Syed Abbas Arch Med Sci Atheroscler Dis State of the Art Paper Anticoagulation and antiplatelet therapy are individually mainstays of treatment for multiple cardiovascular conditions. Antiplatelet therapy, most commonly with dual agents, is vital in the setting of coronary artery disease with acute coronary syndrome requiring percutaneous coronary intervention to prevent in-stent complications. A multitude of cardiovascular conditions with increased thromboembolic risk also require anticoagulation, including atrial fibrillation, venous or arterial thrombosis, and prosthetic heart valves to name a few. There is often an overlap in comorbidities as our patient population ages and becomes more complex, frequently necessitating a combination of both anticoagulation and antiplatelet agents, known as “triple therapy”. To reduce or treat thromboembolic disease states as well as reduce platelet aggregation for coronary stent protection, many patients are placed at an increased bleeding risk without compelling evidence of reduction in major adverse cardiac events. With this comprehensive review of the existing literature, we aim to analyse different strategies and durations of triple therapy medication regimens. Termedia Publishing House 2023-02-28 /pmc/articles/PMC10161787/ /pubmed/37153377 http://dx.doi.org/10.5114/amsad/161172 Text en Copyright: © 2023 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | State of the Art Paper Patail, Haris Sharma, Tanya Bali, Atul D. Isath, Ameesh Aronow, Wilbert S. Haidry, Syed Abbas Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy |
title | Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy |
title_full | Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy |
title_fullStr | Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy |
title_full_unstemmed | Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy |
title_short | Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy |
title_sort | dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy |
topic | State of the Art Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161787/ https://www.ncbi.nlm.nih.gov/pubmed/37153377 http://dx.doi.org/10.5114/amsad/161172 |
work_keys_str_mv | AT patailharis dualantiplatelettherapywithconcomitantanticoagulationcurrentperspectivesontripletherapy AT sharmatanya dualantiplatelettherapywithconcomitantanticoagulationcurrentperspectivesontripletherapy AT baliatuld dualantiplatelettherapywithconcomitantanticoagulationcurrentperspectivesontripletherapy AT isathameesh dualantiplatelettherapywithconcomitantanticoagulationcurrentperspectivesontripletherapy AT aronowwilberts dualantiplatelettherapywithconcomitantanticoagulationcurrentperspectivesontripletherapy AT haidrysyedabbas dualantiplatelettherapywithconcomitantanticoagulationcurrentperspectivesontripletherapy |